RESEARKA

Within-corpus tensions emerge when comparing the null effect directions reported for aspirin-specific interventions against the positive signals from related immune-inflammatory research. Zhang 2026 demonstrated that elevated SII predicts atrial fibrillation recurrence (RR = 2.3, P < 0.001), suggesting systemic inflammation worsens cardiovascular outcomes, but this does not establish aspirin's capacity to reduce SII or improve geroprotective endpoints. A systematic review and meta-analysis evaluated the efficacy and safety of clopidogrel versus aspirin monotherapy for secondary prevention after percutaneous coronary intervention (PCI). This analysis included a GRADE assessment and trial sequential analysis, focusing on long-term survival endpoints in adults with established cardiovascular disease.

Citation Support

• source_1 Flensted-Jensen 2025
• source_2 Saeed 2026
• source_3 Zhu 2026
• source_4 Navarese 2026
• source_5 Yan 2024